Fluconazole
- Generic Name
- Fluconazole
- Brand Names
- Diflucan
- Drug Type
- Small Molecule
- Chemical Formula
- C13H12F2N6O
- CAS Number
- 86386-73-4
- Unique Ingredient Identifier
- 8VZV102JFY
- Background
Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.
- Indication
Fluconazole can be administered in the treatment of the following fungal infections:
1) Vaginal yeast infections caused by Candida
2) Systemic Candida infections
3) Both esophageal and oropharyngeal candidiasis
4) Cryptococcal meningitis
5) UTI (urinary tract infection) by Candida
6) Peritonitis (inflammation of the peritoneum) caused by Candida
A note on fungal infection prophylaxis
Patients receiving bone marrow transplantation who are treated with cytotoxic chemotherapy and/or radiation therapy may be predisposed to candida infections, and may receive fluconazole as prophylactic therapy.
A note on laboratory testing
Obtaining specimens for fungal culture and other important laboratory studies such as serology or pathology is advised before starting fluconazole therapy in order to isolate the organisms to be eliminated through treatment. It is permissible to start therapy before the results are available, however, adjusting the therapy once laboratory results confirm the causative organism may be necessary.
- Associated Conditions
- Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis
Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome
- Conditions
- Candidiasis, OralHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002112
- Locations
- 🇺🇸
California Med Research Group, Fresno, California, United States
🇺🇸UCSF Hosp, San Francisco, California, United States
🇺🇸Johns Hopkins School of Medicine, Baltimore, Maryland, United States
Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis
- Conditions
- MeningitisHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002010
- Locations
- 🇺🇸
HIV Research Group, San Diego, California, United States
🇺🇸Tucson Veterans Administration Med Ctr, Tucson, Arizona, United States
🇺🇸Audie L Murphy Veterans Administration Hosp, San Antonio, Texas, United States
Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients
- Conditions
- Candidiasis, OralHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Schering-Plough
- Target Recruit Count
- 300
- Registration Number
- NCT00002446
- Locations
- 🇺🇸
ViRx Inc, San Francisco, California, United States
🇺🇸Boulevard Comprehensive Care Ctr, Jacksonville, Florida, United States
🇺🇸Miami Veterans Administration Med Ctr, Miami, Florida, United States
A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients
- Conditions
- Candidiasis, OralHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Schering-Plough
- Target Recruit Count
- 500
- Registration Number
- NCT00002399
- Locations
- 🇺🇸
Wayne State Univ / Harper Hosp, Detroit, Michigan, United States
🇦🇷Centro de Micologia / Facultad de Medicina UBA, Buenos Aires, Argentina
🇪🇹Faculty of Medicine / Dept of Internal Medicine, Addis Ababa, Ethiopia
Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy
- Conditions
- CandidiasisMycosesHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002038
- Locations
- 🇺🇸
Pfizer Central Research, Groton, Connecticut, United States
A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis
- Conditions
- Meningitis, CryptococcalHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002305
- Locations
- 🇺🇸
UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸Emory Univ School of Medicine, Atlanta, Georgia, United States
🇺🇸DeKalb Gen Hosp, Decatur, Georgia, United States
A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections
- Conditions
- MycosesHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002277
- Locations
- 🇺🇸
Dr Temple Williams, Houston, Texas, United States
🇺🇸M D Anderson Cancer Ctr, Houston, Texas, United States
🇺🇸Dr Layne Gentry, Houston, Texas, United States
A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common
- Conditions
- MycosesCoccidioidomycosisHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002325
- Locations
- 🇺🇸
Tucson Veterans Administration Med Ctr, Tucson, Arizona, United States
🇺🇸McDowell Clinic, Phoenix, Arizona, United States
🇺🇸Dr Lawrence Cone, Rancho Mirage, California, United States
Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.
- Conditions
- Candidiasis, EsophagealHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Janssen Pharmaceuticals
- Registration Number
- NCT00002132
- Locations
- 🇺🇸
Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸Univ of Missouri at Kansas City School of Medicine, Kansas City, Missouri, United States
🇺🇸Dr Eskild A Petersen, Tucson, Arizona, United States
A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients With AIDS
- Conditions
- Candidiasis, OralHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002282
- Locations
- 🇺🇸
Dr Robert Larsen, Los Angeles, California, United States
🇺🇸SUNY / Health Sciences Ctr at Stony Brook, Stony Brook, New York, United States
🇺🇸Buckley Braffman Stern Med Associates, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.